

ACIST Diastolic Pressure Ratio (dPR)

Non-hyperemic index for coronary physiology



Reducing costs, time and patient discomfort

ACIST diastolic pressure ratio (dPR), using the ACIST Rxi[®] Rapid Exchange System, provides a non-hyperemic alternative for physiological assessment of coronary disease. Non-hyperemic pressure ratios, such as dPR, may reduce patient discomfort*, cost** and procedural time.***




ACIST Rxi[®] Rapid Exchange System

Uses Navvus MicroCatheter, the go-to alternative to traditional pressure wires, enabling the physician to use their 0.014" guidewire of choice for reliable assessment of coronary physiology.



ACIST dPR algorithm

ACIST dPR is the ratio of Pd to Pa at the peak-to-peak midpoint, averaged over 5 consecutive heartbeats. ACIST dPR does not rely on an ECG signal to make the calculation.



ACIST dPR by the numbers (compared to iFR_{calc})¹

0.89
dPR cutpoint

0.999
AUC

98.3%
Sensitivity

99.2%
Specificity

98.3%
PPV

99.2%
NPV

Analysis of the ACIST FFR Study¹

Purpose

The data collected during the ACIST-FFR clinical study was retrospectively assessed by an independent, physiologic core laboratory to support ACIST's dPR algorithm on the ACIST RXi system.

Methods

The dPR value was calculated by the application of ACIST's fully automated off-line dPR software algorithm. iFR_{calc} was calculated off-line, by the same core lab, based on the original description of its derivation to determine a final value for iFR .²

11
sites

179
patients


Results

Diagnostic accuracy of dPR
(cutpoint of 0.89) referenced to
 iFR_{calc} (0.89) was **98.88%**

Key points

- ACIST dPR is highly correlated with iFR_{calc}
- ACIST dPR provides similar diagnostic accuracy as iFR_{calc}

Passing-Bablok Comparison between dPR (cutpoint 0.89) and iFR_{calc} (0.89)



Learn more about ACIST dPR* and the Navvus[®] Rapid Exchange Pressure MicroCatheter at [ACIST.com](https://www.acist.com)

*ACIST dPR is available in select markets

^{*}Cost savings based on the reduced cost of utilizing a resting approach compared to conventional FFR and respective cost of administration of hyperemic agent (adenosine).

^{**} when comparing resting index (iFR , dPR, Pd/Pa) to FFR with adenosine induced hyperemia

^{***} Reduced side effect profile when comparing resting approach (iFR , dPR, Pd/Pa) to FFR with adenosine induced hyperemia

1. Data on file TR-07879

2. Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol. 2012;59(15):1392-1402. doi:10.1016/j.jacc.2011.11.003.

ACIST, ACIST RXi and Navvus are trademarks of ACIST Medical Systems, Inc. ACIST Medical Systems, Inc., reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized ACIST representative for the most current information.